Clinicians, who may have only seen the media headlines following discussion of reviews
which deal with randomized controlled trials of neuraminidase inhibitor drug use in mild …

For many years, antiviral treatment of influenza has consisted of monotherapy with a
neuraminidase inhibitor. The Food and Drug Administration (FDA) approved the …

Introduction: Over the last century several influenza outbreaks have traversed the globe,
most recently the influenza A (H1N1) 2009 pandemic. On each occasion, a highly …

It has been estimated that, globally, seasonal influenza epidemics result in 3–5 million
severe infections, excessive hospitalizations, and 250 000− 500 000 deaths each year [1] …

Although there has been controversy over the level of evidence for patient benefit, a growing
body of evidence suggests that treatment of influenza with NAIs is associated with improved …

Options for influenza therapy are currently limited to one class of drug, the neuraminidase
inhibitors. Amidst concerns about drug resistance, much effort has been placed on the …

Seasonal influenza epidemics and periodic pandemics are important causes of morbidity
and mortality. Patients with chronic co‐morbid illness, those at the extremes of age and …

Comment www. thelancet. com Vol 384 August 2, 2014 387 to cause severe illness and
death. Although observational studies have limitations and weaknesses compared with …

Annual influenza epidemics and periodic pandemics result in excess hospital admissions.
Hospitalization typically occurs in those with underlying medical conditions, those at the …

We aimed to study factors influencing outcomes of adults hospitalised for seasonal and
pandemic influenza. Individual-patient data from three Asian cohorts (Hong Kong …